31May 2015

Acinetobacter baumannii: Correlation between Biofilm Production and Multidrug Resistance

  • Department of Medical Microbiology and Immunology, Mansoura Faculty of Medicine, Mansoura, Egypt
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: Recently, Acinetobacter baumannii has received much interest owing to its increasing enrollment in a number of serious infections in healthcare settings. Aim: To assess in-vitro biofilm formation and examine the correlation between biofilm production and antibiotic resistance among clinical isolates of A. baumannii. Materials and methods:A prospective cohort study was conducted over a period of 12 months starting from January 2014 to December 2014. A total of 56 A. baumannii isolates from different clinical specimens were recovered from patients admitted to the intensive care unit (ICU) of Emergency Hospital, Mansoura University, Mansoura, Egypt. Antimicrobial susceptibility testing was evaluated by the Kirby-Bauer s disc diffusion method. Biofilm formation was studied by both tube method and microtiter plate assay. Results:A. baumannii isolates were resistant to most of the tested antibiotics except polymyxin B. Of these isolates, 62.5% were able to produce biofilms as shown by both tube method and microtiter plate assay. The highest tendency of biofilm production was shown by A. baumannii isolated from endotracheal aspirates (51.4%). About 77.1% of the biofilm-forming isolates were multidrug-resistant (MDR). Conclusion: The present study revealed a high predilection among A. baumanniiisolates to form biofilm, together with a significant association between biofilm production and MDR.

  1. Peleg AY, Seifert H, Paterson DL.Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin Microbiol Rev 2008 Jul; 21(3):538-582.
  2. Cisneros JM, Reyes MJ, Pachon J, Becerril B, Caballero FJ, Garcia-Garmendia JL, et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996; 22:1026-1032.
  3. Chaari A, Mnif B, Bahloul M, Mahjoubi F, Chtara K, Turki O, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors. Int J Infect Dis 2013; 17:1225-1228.
  4. Yang M, Hu Z, Hu F. Nosocomial meningitis caused by Acinetobacter baumannii: risk factors and their impact on patient outcomes and treatments. Future Microbiol 2012; 7:787-793.
  5. Gaynes R, Edwards JR, National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by Gram negative bacilli. Clin Infect Dis 2005; 41:848-854.
  6. Guerrero DM, Perez F, Conger NG, Solomkin JS, Adams MD, Rather PN, et al. Acinetobacter baumannii-associated skin and soft tissue infections: recognizing a broadening spectrum of disease. Surg Infect (Larchmt) 2010; 11:49-57.
  7. Yoon EJ, Courvalin P, Grillot-Courvalin C. RND-type efflux pumps in multidrug-resistant clinical isolates of Acinetobacter baumannii: major role for AdeABC overexpression and AdeRS mutations. Antimicrob Agents Chemother 2013; 57:2989-2995.
  8. Stickler DJ.Bacterial biofilms in patients with indwelling urinary catheters. Nat Clin Pract Urol 2008 Nov; 5(11):598-608.
  9. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358:135-138.
  10. Gurung J, Khyriem AB, Banik A, Lyngdoh WV, Choudhury B, Bhattacharyya P.Association of biofilm production with multidrug resistance among clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa from intensive care unit. Indian J Crit Care Med 2013 Jul; 17(4):214-218.
  11. Mansour MK, Abd Rhman SA. Biofilm Formation and Its Association with Multiple Drug Resistance among Clinical Isolates of Acinetobacter baumannii. Egyptian J Med Microbiol 2012; 21(2):81-88.
  12. Koneman EW, Allen SD, Janda WM, Schreckenberger RC, Winn WC. Introduction to microbiology, part II: guidelines for the collection, transport, processing, analysis and reporting of cultures from specific specimen sources. In: Koneman EW, Allen SD, Janda WM, Schreckenberger RC, Winn WC (eds). Color Atlas and Textbook of Diagnostic Microbiology, 5th edn. Lippincot-Raven: Philadelphia, 1997, pp 121-
  13. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility testing; Twenty third Informational Supplement. CLSI document M100-S23.Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
  14. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum beta lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10:867-
  15. Christensen GD, Simpson WA, Bisno AL, Beachey EH. Adherence of slime-producing strains of Staphylococcusepidermidis to smooth surfaces. Infect Immun 1982; 37:318-326.
  16. Christensen GD, Simpson WA, Younger JJ, Baddour LM, Barrett FF, Melton DM, et al. Adherence of coagulase-negative Staphylococci to plastic tissue culture plates: a quantitative model for the adherence of Staphylococci to medical devices. J Clin Microbiol 1985; 22(6):996-
  17. Stepanović S, Vuković D, Hola V, Di Bonaventura G, Djukić S, Cirković I, et al. Quantification of biofilm in microtitre plates: overview of testing conditions and practical recommendations for assessment of biofilm production by Staphylococci. APMIS 2007; 115:891-899.
  18. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42:692-699.
  19. Shanthi M, Sekar U. Multi-drug resistant Pseudomonasaeruginosa and Acinetobacterbaumannii infections among hospitalized patients: risk factors and outcomes. J Assoc Physicians India 2009; 8(11):687-693.
  20. Maragakis L, Perl TM. Acinetobacterbaumannii: epidemiology, antimicrobial resistance, and treatment options. Clinical infectious diseases 2008; 46(8):1254-1263.
  21. Mostofi S, Mirnejad R, Masjedian F. Multi-drug resistance in Acinetobacter baumannii strains isolated from the clinical specimens of three hospitals in Tehran-Iran. Afr J Microbiol Res 2011; 5:4467-4470.
  22. Dheepa M, Vinitha L, Appolaraju B. Comparison of biofilm production and MDR in Clinical Isolates of Acinetobacterbaumannii from a tertiary care hospital in South India. Int J pharm Biomed Sci 2011; 2(4):103-107.
  23. Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, Ho SW, et al. Pandrug-resistant Acinetobacterbaumannii causing nosocomial infections in a university hospital, Taiwan. Emerging Infect Dis 2002; 8:827-832.
  24. ME, Koletsi PK, Bliziotis IA.The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacterbaumannii and Pseudomonas aeruginosa. J Med Microbiol 2006; 55:1619-1629.
  25. Dent LL, Marshall DR, Pratap S, Hulette RB. Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infect Dis 2010 Jul 7; 10:196.
  26. De Francesco MA, Ravizzola G, Peroni L, Bonfanti C, Manca N.Prevalence of multidrug-resistant Acinetobacterbaumannii and Pseudomonasaeruginosa in an Italian hospital. J Infect Public Health 2013 Jun; 6(3):179-185.
  27. Begum S, Hasan F, Hussain S, Shah AA.Prevalence of multi drug resistant Acinetobacterbaumannii in the clinical samples from Tertiary Care Hospital in Islamabad, Pakistan. Pak J Med Sci 2013; 29(5):1253-1258.
  28. Soroush S, Haghi-Ashtiani MT, Taheri-Kalani M, Emaneini M, Aligholi M, Sadeghifard N, et al.Antimicrobial resistance of nosocomial strain of Acinetobacterbaumannii in Children\\\'s Medical Center of Tehran: a 6- year prospective study. Acta Med Iran 2010; 48(3):178-184.
  29. Mak JK, Kim MJ, Pharm J, Tapsall J, White PA.Antibiotic resistance determinants in nosocomial strains of multidrug resistant Acinetobacterbaumannii. J Antimicrob Chemother 2009; 63:47-54.
  30. Behera B, Mathur P, Das A, Kapil A, Gupta B, Bhoi S, et al.Evaluation of susceptibility testing methods for polymyxin. Int J Infect Dis 2009; 996:e1-6.
  31. Bhose S, Barapatre R, Ghosh AK.Emergence of Multidrug Resistant Acinetobacterbaumannii in an ICU. Natl J Integr Res Med 2013; 4(2):11-14.
  32. Ko KS, Suh J, Kwon KT, Jung SI, Park KH, Kang KI, et al.High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacterbaumannii isolates from Korea. J Antimicrob Chemother 2007; 60:1163-1167.
  33. Mohajeri P, Farahani A, Feizabadi MM, Davoodabadi A, Noroozi B.The Prevalence of ESBL Isolates of Acinetobacterbaumannii Using Pulsed-Field Gel Electrophoresis. ZJRMS 2014; 16(11):20-23.
  34. Safari M, Mozaffari Nejad AS, Bahador A, Jafari R, Alikhani MY. Prevalence of ESBL and MBL encoding genes in Acinetobacterbaumannii strains isolated from patients of intensive care units (ICU). Saudi J Biol Sci 2015; 22(4):424-429.
  35. Longo F, Vuotto C, Donelli G.Biofilm formation in Acinetobacterbaumannii. New Microbiol 2014; 37:119-127.
  36. Mathur T, Singhal S, Khan S, Upadhyay DJ, Fatma T, Rattan A.Detection of biofilm formation among the clinical isolates of Staphylococci: an evaluation of three different screening methods. Indian J Med Microbiol 2006; 24(1):25-29.
  37. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: A common cause of persistent infections. Science 1999; 284:1318-1322.
  38. Rodriguez-Bano J, Marti S, Soto S, Fernandez-Cuenca F, Cisneros JM, Pachon J, et al.Biofilm formation in Acinetobacterbauman?nii: associated features and clinical implications. Clin Microbiol Infect 2008; 14(3):276-278.
  39. Rao RS, Karthika RU, Singh SP, Shashikala P, Kanungo R, Jayachandran S, et al.Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates of Acinetobacterbaumannii. Indian J Med Microbiol 2008; 26:333-337.
  40. Donlan R.Biofilms and device associated infections. Emerg Infect Dis 2001; 7(2):277-281.
  41. Hassan A, Usman J, Kaleem F, Omair M, Khalid A, Iqbal M.Evaluation of different detection methods of biofilm formation in the clinical isolates. Braz J Infect Dis 2011; 15(4):305-311.
  42. Nahar A, Anwar S, Ruhul M. Association of Biofilm Formation with Antimicrobial Resistance Among the Acinetobacter Species in A Tertiary Care Hospital in Bangladesh. J Medicine 2013; 14:28-32.
  43. Abdi-Ali A, Hendiani S, Mohammadi P, Gharavi S.Assessment of biofilm formation and resistance to imipenem and ciprofloxacin among clinical isolates of Acinetobacterbaumannii in Tehran. Jundishapur J Microbiol 2014; 7(1):e8606.
  44. Patel R.Biofilms and antimicrobial resistance. Clin Orthop Relat Res 2005 Aug; (437):41-47.

[Rania Abd El-Hamid El-Kady (2015); Acinetobacter baumannii: Correlation between Biofilm Production and Multidrug Resistance Int. J. of Adv. Res. 3 (May). 691-699] (ISSN 2320-5407). www.journalijar.com

Rania Abd El-Hamid El-kady

Download Full Paper

Download PDF No. of Downloads: 25 | No. of Views: 81